MODERNA INC

NASDAQ: MRNA (Moderna, Inc.)

Kemas kini terakhir: 6 hari lalu, 9:39PM

24.16

-1.82 (-7.01%)

Penutupan Terdahulu 25.98
Buka 25.05
Jumlah Dagangan 9,563,493
Purata Dagangan (3B) 11,277,795
Modal Pasaran 9,440,124,928
Harga / Jualan (P/S) 4.36
Harga / Buku (P/B) 1.04
Julat 52 Minggu
22.28 (-7%) — 48.92 (102%)
Margin Keuntungan -105.67%
Margin Operasi (TTM) -972.22%
EPS Cair (TTM) -8.73
Pertumbuhan Hasil Suku Tahunan (YOY) -35.30%
Jumlah Hutang/Ekuiti (D/E MRQ) 7.40%
Nisbah Semasa (MRQ) 4.22
Aliran Tunai Operasi (OCF TTM) -3.05 B
Aliran Tunai Bebas Leveraj (LFCF TTM) -3.20 B
Pulangan Atas Aset (ROA TTM) -15.84%
Pulangan Atas Ekuiti (ROE TTM) -29.34%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Bercampur
Biotechnology (Global) Bercampur Bercampur
Stok Moderna, Inc. Bercampur Menurun

AISkor Stockmoo

-1.3
Konsensus Penganalisis 0.5
Aktiviti Orang Dalam -3.5
Volatiliti Harga 0.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal -4.0
Purata -1.30

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
MRNA 9 B - - 1.04
MESO 2 B - - 3.70
TSHA 1 B - - 5.08
SANA 1 B - - 6.10
NTLA 1 B - - 1.32
ORIC 1 B - - 2.83

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 7.28%
% Dimiliki oleh Institusi 73.67%
Julat 52 Minggu
22.28 (-7%) — 48.92 (102%)
Julat Harga Sasaran
18.00 (-25%) — 63.00 (160%)
Tinggi 63.00 (Piper Sandler, 160.76%) Beli
Median 25.00 (3.48%)
Rendah 18.00 (Leerink Partners, -25.50%) Jual
Purata 30.78 (27.40%)
Jumlah 2 Beli, 4 Pegang, 3 Jual
Harga Purata @ Panggilan 25.12
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Leerink Partners 21 Nov 2025 18.00 (-25.50%) Jual 23.72
Piper Sandler 21 Nov 2025 63.00 (160.76%) Beli 23.72
RBC Capital 21 Nov 2025 25.00 (3.48%) Pegang 23.72
B of A Securities 10 Nov 2025 21.00 (-13.08%) Jual 24.76
Barclays 07 Nov 2025 25.00 (3.48%) Pegang 24.54
Citigroup 23 Oct 2025 28.00 (15.89%) Pegang 26.25
JP Morgan 23 Oct 2025 25.00 (3.48%) Jual 26.25
UBS 23 Oct 2025 40.00 (65.56%) Beli 26.25
Morgan Stanley 10 Oct 2025 32.00 (32.45%) Pegang 26.83
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
HOGE STEPHEN - 25.05 -1,306 -32,681
KLINGER SHANNON THYME - 25.05 -647 -16,241
MOCK JAMES M - 25.50 -534 -13,511
Jumlah Keseluruhan Kuantiti Bersih -2,487
Jumlah Keseluruhan Nilai Bersih ($) -62,432
Purata Pembelian Keseluruhan ($) -
Purata Jualan Keseluruhan ($) 25.16
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
HOGE STEPHEN Pegawai 01 Dec 2025 Dibuang (-) 316 24.16 7,635
HOGE STEPHEN Pegawai 01 Dec 2025 Pelaksanaan pilihan 652 - -
KLINGER SHANNON THYME Pegawai 01 Dec 2025 Dibuang (-) 113 24.16 2,730
KLINGER SHANNON THYME Pegawai 01 Dec 2025 Pelaksanaan pilihan 233 - -
HOGE STEPHEN Pegawai 28 Nov 2025 Dibuang (-) 295 25.98 7,664
HOGE STEPHEN Pegawai 28 Nov 2025 Pelaksanaan pilihan 610 - -
KLINGER SHANNON THYME Pegawai 28 Nov 2025 Dibuang (-) 160 25.98 4,157
KLINGER SHANNON THYME Pegawai 28 Nov 2025 Pelaksanaan pilihan 329 - -
MOCK JAMES M Pegawai 28 Nov 2025 Dibuang (-) 160 25.98 4,157
MOCK JAMES M Pegawai 28 Nov 2025 Pelaksanaan pilihan 329 - -
HOGE STEPHEN Pegawai 26 Nov 2025 Dibuang (-) 695 25.01 17,382
HOGE STEPHEN Pegawai 26 Nov 2025 Pelaksanaan pilihan 1,437 - -
KLINGER SHANNON THYME Pegawai 26 Nov 2025 Dibuang (-) 374 25.01 9,354
KLINGER SHANNON THYME Pegawai 26 Nov 2025 Pelaksanaan pilihan 773 - -
MOCK JAMES M Pegawai 26 Nov 2025 Dibuang (-) 374 25.01 9,354
MOCK JAMES M Pegawai 26 Nov 2025 Pelaksanaan pilihan 773 - -
Papar semua
Tarikh Jenis Butiran
20 Nov 2025 Pengumuman Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates
20 Nov 2025 Pengumuman Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management
19 Nov 2025 Pengumuman Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities
18 Nov 2025 Pengumuman Moderna to Present at Upcoming Piper Sandler's 37th Annual Healthcare Conference on December 2, 2025
06 Nov 2025 Pengumuman Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates
03 Nov 2025 Pengumuman Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma
23 Oct 2025 Pengumuman Moderna Named a Top Employer by Science for Eleventh Consecutive Year
23 Oct 2025 Pengumuman Moderna to Host Investor Event - Analyst Day
22 Oct 2025 Pengumuman Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint
19 Oct 2025 Pengumuman Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025
16 Oct 2025 Pengumuman Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
12 Oct 2025 Pengumuman Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress
24 Sep 2025 Pengumuman Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK
23 Sep 2025 Pengumuman Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans
19 Sep 2025 Pengumuman Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories
16 Sep 2025 Pengumuman Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans
12 Sep 2025 CNBC Pfizer, Moderna shares fall on report that Trump officials will link child deaths to Covid shots
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda